These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6631013)

  • 1. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.
    Livingston PO; DeLeo AB; Jones M; Oettgen HF
    J Immunol; 1983 Nov; 131(5):2601-5. PubMed ID: 6631013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of levamisole on methylcholanthrene-induced tumor. I. Its antitumor effect and immunological mechanism].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1262-8. PubMed ID: 7184454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
    Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO; Calves MJ; Natoli EJ
    J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.
    Palladino MA; Srivastava PK; Oettgen HF; DeLeo AB
    Cancer Res; 1987 Oct; 47(19):5074-9. PubMed ID: 3497717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
    De Leo AB; Becker M; Lu L; Law LW
    Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immunity to solubilized tumor antigens of a methylcholanthrene-induced sarcoma with a migration inhibition assay.
    Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW; Natori T; Law LW
    J Immunol; 1978 Jun; 120(6):1981-5. PubMed ID: 659888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy combining tumor necrosis factor with tumor-specific antibody against Meth A sarcoma.
    Satomi N; Sakurai A; Haranaka R; Haranaka K
    J Biol Response Mod; 1989 Oct; 8(5):528-38. PubMed ID: 2677250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of different doses of cyclophosphamide on the immune response of mice with a methylcholanthrene-induced sarcoma].
    Gordienko SP; Bergol'ts VM
    Vopr Onkol; 1973; 19(11):54-60. PubMed ID: 4785975
    [No Abstract]   [Full Text] [Related]  

  • 11. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
    Coggin JH
    Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells.
    DuBois GC; Appella E; Law LW; DeLeo AB; Old LJ
    Cancer Res; 1980 Nov; 40(11):4204-8. PubMed ID: 7471061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of the rhythm of cyclophosphamide administration on its antitumor action and on the immune response of mice with methylcholanthrene-induced sarcoma].
    Gordienko SP; Bergol'ts VM; Botsmanov KV
    Biull Eksp Biol Med; 1974 Jul; 78(7):87-90. PubMed ID: 4451721
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells.
    Tamerius JD; Hellström I
    J Immunol; 1974 Jun; 112(6):1987-96. PubMed ID: 4825783
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of antitumor immunity by tumor cells treated with abrin.
    Shionoya H; Arai H; Koyanagi N; Ohtake S; Kobayashi H; Kodama T; Kato H; Tung TC; Lin JY
    Cancer Res; 1982 Jul; 42(7):2872-6. PubMed ID: 7083176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
    Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen.
    Ono T; Sato S; Kimura N; Tanaka M; Shibuya A; Old LJ; Nakayama E
    Int J Cancer; 2000 Dec; 88(6):845-51. PubMed ID: 11093803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases.
    Rodolfo M; Melani C; Zilocchi C; Cappetti B; Luison E; Arioli I; Parenza M; Canevari S; Colombo MP
    Cancer Res; 1998 Dec; 58(24):5812-7. PubMed ID: 9865740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.
    Henderson DC; Parker D; Turk JL
    Immunology; 1980 Jan; 39(1):1-9. PubMed ID: 7380461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.